https://www.biopharmawatch.com/blog/fda-calendar-q2-2026-key-pdufa-dates-upcoming-approvals BiopharmaWatch en 2026-09-01T07:16:19.006Z FDA Calendar: Upcoming PDUFA Dates and Drug Approval Decisions https://www.biopharmawatch.com/blog/Upcoming_Penny_Stock_Catalysts_in_June_2025_for_Biotech_and_Pharma_-_FDA_Calendar_and_PDUFA_Dates_to_Watch BiopharmaWatch en 2026-09-01T07:15:55.843Z Biotech Penny Stock Catalysts: FDA Calendar and PDUFA Dates for Small-Cap Pharma Stocks https://www.biopharmawatch.com/blog/fda-calendar-september-2026 BiopharmaWatch en 2026-09-01T07:15:28.766Z FDA Calendar September 2026: A Critical Look at Upcoming Approvals https://www.biopharmawatch.com/news/NVS/novartis-remibrutinib-phase-iii-results BiopharmaWatch en 2026-09-01T05:15:00.000Z Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials https://www.biopharmawatch.com/news/YDES/yd-bio-revenue-growth-2026 BiopharmaWatch en 2026-09-01T03:46:48.000Z YD Bio 公布截至2026年6月30日止六個月財務業績 https://www.biopharmawatch.com/news/PMVP/pmv-pharma-pricing-50-million-public-offering BiopharmaWatch en 2026-09-01T03:03:00.000Z PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities https://www.biopharmawatch.com/news/ADMA/berger-montague-investigates-adma-biologics-board BiopharmaWatch en 2026-09-01T02:39:17.085Z Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA) https://www.biopharmawatch.com/news/BETR/betterlife-pharma-us100-million-offering BiopharmaWatch en 2026-09-01T00:48:10.980Z BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants https://www.biopharmawatch.com/news/ROVA/altrova-health-q3-fiscal-2026-results BiopharmaWatch en 2026-09-01T00:42:34.571Z Altrova Health Reports Third Quarter Fiscal 2026 Financial Results https://www.biopharmawatch.com/news/DTR/diagnostear-technologies-private-placement-units BiopharmaWatch en 2026-09-01T00:42:23.565Z DiagnosTear Technologies Inc. Announces Private Placement of Units https://www.biopharmawatch.com/news/CHER/cheelcare-fiscal-2026-results-curio-update BiopharmaWatch en 2026-09-01T00:42:10.675Z Cheelcare Announces Fourth Quarter and Fiscal 2026 Financial Results and Provides Curio Update https://www.biopharmawatch.com/news/TLT/theralase-releases-q2-2026-financial-statements BiopharmaWatch en 2026-09-01T00:40:37.538Z Theralase(R) Releases Q2 2026 Financial Statements https://www.biopharmawatch.com/news/SHRX/sharp-therapeutics-h1-2026-results-update BiopharmaWatch en 2026-09-01T00:40:24.537Z Sharp Therapeutics Corp. Reports First Half 2026 Results and Development Update https://www.biopharmawatch.com/news/DTC/defence-therapeutics-expands-radiopharmaceutical-strategy BiopharmaWatch en 2026-09-01T00:40:11.365Z Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs https://www.biopharmawatch.com/news/MRNA/moderna-upsized-convertible-senior-notes-offering BiopharmaWatch en 2026-09-01T00:36:28.377Z Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes https://www.biopharmawatch.com/news/CVS/cvs-pharmacy-minuteclinic-offering-updated-flu-vaccines BiopharmaWatch en 2026-09-01T00:34:57.682Z CVS Pharmacy(R) and MinuteClinic(R) Now Offering Updated Flu Vaccines Nationwide https://www.biopharmawatch.com/news/LOBE/lobe-sciences-upsizes-private-placement BiopharmaWatch en 2026-09-01T00:33:57.459Z Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement https://www.biopharmawatch.com/news/PTGX/protagonist-therapeutics-fda-approval-mimrylo-polycythemia-vera BiopharmaWatch en 2026-09-01T00:33:34.891Z Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera https://www.biopharmawatch.com/news/LOBE/lobe-sciences-new-cfo-appointment BiopharmaWatch en 2026-09-01T00:33:21.802Z Lobe Sciences Expands Leadership Team with New CFO Appointment https://www.biopharmawatch.com/news/TNON/tenon-medical-private-placement-offering BiopharmaWatch en 2026-09-01T00:33:09.752Z Tenon Medical Announces Pricing of $3M Private Placement Offering https://www.biopharmawatch.com/news/BIIB/canadas-drug-agency-recommends-leqembi-reimbursement BiopharmaWatch en 2026-08-31T23:30:47.000Z Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease https://www.biopharmawatch.com/news/TLX/telix-appoints-david-gill-chair BiopharmaWatch en 2026-08-31T22:21:00.000Z Telix Appoints David Gill as Chair https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-soho-2026-presentations BiopharmaWatch en 2026-08-31T22:05:00.000Z Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-epetraborole-polycythemia-vera-soho-2026 BiopharmaWatch en 2026-08-31T22:00:00.000Z AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting https://www.biopharmawatch.com/news/IRON/disc-medicine-soho-2026-presentations BiopharmaWatch en 2026-08-31T22:00:00.000Z Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting https://www.biopharmawatch.com/news/YDES/yd-bio-limited-financial-results-june-2026 BiopharmaWatch en 2026-08-31T22:00:00.000Z YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026 https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-oversubscribed-public-offering BiopharmaWatch en 2026-08-31T21:58:00.000Z Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering https://www.biopharmawatch.com/news/ACET/adicet-bio-inducement-grant-nasdaq-rule-5635 BiopharmaWatch en 2026-08-31T21:39:00.000Z Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/JNJ/johnson-johnson-investor-conference-call-q3-results BiopharmaWatch en 2026-08-31T21:08:00.000Z Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-morgan-stanley-conference-2023 BiopharmaWatch en 2026-08-31T20:30:00.000Z Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/ZURA/zura-bio-participate-cantor-healthcare-conference BiopharmaWatch en 2026-08-31T20:30:00.000Z Zura Bio to Participate in the Cantor Global Healthcare Conference https://www.biopharmawatch.com/news/LFWD/lifeward-appoints-josh-hexter-ceo-rami-aviram-cfo BiopharmaWatch en 2026-08-31T20:15:00.000Z Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer https://www.biopharmawatch.com/news/ENOV/enovis-participate-2026-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-31T20:15:00.000Z Enovis to Participate in the 2026 Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/SIBN/si-bone-presents-morgan-stanley-healthcare-conference-2026 BiopharmaWatch en 2026-08-31T20:09:00.000Z SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026 https://www.biopharmawatch.com/news/ALGN/quentin-blackford-joins-align-technology-board BiopharmaWatch en 2026-08-31T20:08:00.000Z Quentin Blackford to Join Align Technology Board of Directors https://www.biopharmawatch.com/news/VIR/vir-biotechnology-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-08-31T20:05:00.000Z Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/NPCE/neuropace-participate-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-31T20:05:00.000Z NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-hc-wainwright-conference BiopharmaWatch en 2026-08-31T20:05:00.000Z TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/KYNB/kyntra-bio-reduces-royalty-financing-obligation BiopharmaWatch en 2026-08-31T20:05:00.000Z Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation https://www.biopharmawatch.com/news/IVA/inventiva-appoints-chris-benecchi-coo BiopharmaWatch en 2026-08-31T20:05:00.000Z Inventiva nomme Chris Benecchi au poste de Chief Operating Officer https://www.biopharmawatch.com/news/IVA/inventiva-appoints-chris-benecchi-coo BiopharmaWatch en 2026-08-31T20:05:00.000Z Inventiva Appoints Chris Benecchi as Chief Operating Officer https://www.biopharmawatch.com/news/SYK/stryker-acquires-zurimed-enhance-shoulder-offering BiopharmaWatch en 2026-08-31T20:05:00.000Z Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-labs-sci-210-autism-trial-enrollment BiopharmaWatch en 2026-08-31T20:03:00.000Z SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial https://www.biopharmawatch.com/news/PMVP/pmv-pharma-proposed-public-offering-securities BiopharmaWatch en 2026-08-31T20:02:00.000Z PMV Pharma Announces Proposed Public Offering of Securities https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-investor-conferences-2026 BiopharmaWatch en 2026-08-31T20:01:00.000Z Arcturus Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/GRAL/grail-presentation-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-08-31T20:01:00.000Z GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/KMTS/kestra-medical-technologies-q1-2027-results BiopharmaWatch en 2026-08-31T20:01:00.000Z Kestra Medical Technologies to Report First Quarter Fiscal 2027 Financial Results on September 14 https://www.biopharmawatch.com/news/PMVP/pmv-pharmaceuticals-updated-rezatapopt-ovarian-cancer-data BiopharmaWatch en 2026-08-31T20:01:00.000Z PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial https://www.biopharmawatch.com/news/WAT/wellinks-appoints-agwunobi-waters-board-directors BiopharmaWatch en 2026-08-31T19:51:00.000Z Wellinks Appoints Andrew Agwunobi and Mike Waters to Board of Directors and Expands Management Team https://www.biopharmawatch.com/news/ONC/beone-medicines-us-government-agreement-cancer-medicines BiopharmaWatch en 2026-08-31T19:00:00.000Z BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines https://www.biopharmawatch.com/news/HIMS/hims-enters-australia-asia-pacific-expansion BiopharmaWatch en 2026-08-31T19:00:00.000Z Hims Enters Australia, Marking First Expansion into the Asia-Pacific Market https://www.biopharmawatch.com/news/EXEL/exelixis-patent-litigation-update-msn-laboratories BiopharmaWatch en 2026-08-31T18:30:00.000Z Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories https://www.biopharmawatch.com/news/IDXX/idexx-laboratories-participate-morgan-stanley-conference BiopharmaWatch en 2026-08-31T18:00:00.000Z IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/ONC/beone-medicines-phase-3-results-her2-cancer BiopharmaWatch en 2026-08-31T17:25:00.000Z BeOne Medicines gibt neue Überlebensdaten aus Phase-3-Studien bekannt, die den Nutzen von ZIIHERA-haltigen Therapien bei HER2-positivem gastroösophagealem Krebs in der Erstlinienbehandlung untermauern https://www.biopharmawatch.com/news/ONC/beone-medicines-phase-3-her2-cancer-results BiopharmaWatch en 2026-08-31T17:25:00.000Z Samenvatting: BeOne Medicines kondigt nieuwe overlevingsgegevens uit Fase 3-studie aan die het voordeel bevestigen van behandelregimes met ZIIHERA bij eerstelijnsbehandeling van HER2-positieve gastro-oesofageale kanker https://www.biopharmawatch.com/news/TNON/wallachbeth-capital-closes-tenon-medical-private-placement BiopharmaWatch en 2026-08-31T16:30:00.000Z WallachBeth Capital Announces Closing of Tenon Medical https://www.biopharmawatch.com/news/BTMD/biotecanada-2026-gold-leaf-award-winners BiopharmaWatch en 2026-08-31T14:49:00.000Z BIOTECanada Announces 2026 Gold Leaf Award Winners, Recognizing Excellence Across Canada’s Biotechnology Ecosystem https://www.biopharmawatch.com/news/HLF/herbalife-reaffirms-guidance-2026 BiopharmaWatch en 2026-08-31T13:54:00.000Z Herbalife Reaffirms Third Quarter and Full Year 2026 Guidance https://www.biopharmawatch.com/news/ONC/beone-medicines-phase-3-results-ziihera-gea-treatment BiopharmaWatch en 2026-08-31T13:07:00.000Z Riassunto: BeOne Medicines annuncia i nuovi dati sulla sopravvivenza di Fase 3 a supporto del beneficio dei regimi a base di ZIIHERA nel trattamento di prima linea dei tumori gastroesofagei (GEA) HER2-positivi https://www.biopharmawatch.com/news/BIO/bio-rad-fireside-chat-wells-fargo-healthcare-conference BiopharmaWatch en 2026-08-31T13:00:00.000Z Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/AIM/aim-immunotech-patent-ampligen-pembrolizumab-cancer BiopharmaWatch en 2026-08-31T12:51:00.000Z AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039 https://www.biopharmawatch.com/news/PFSA/profusa-compliance-nasdaq-requirement BiopharmaWatch en 2026-08-31T12:50:00.000Z Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement https://www.biopharmawatch.com/news/DARE/dare-bioscience-nih-funding-dare-ptb2-preterm-birth BiopharmaWatch en 2026-08-31T12:44:00.000Z Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth https://www.biopharmawatch.com/news/ONMD/onemednet-iRWD-platform-ai-drug-development BiopharmaWatch en 2026-08-31T12:35:00.000Z OneMedNet’s iRWD Platform Enables Rapid Feasibility-to-Delivery for Leading AI-Driven Drug Development Company https://www.biopharmawatch.com/news/LXRX/lexicon-sotagliflozin-soloist-whf-analysis BiopharmaWatch en 2026-08-31T12:30:31.000Z Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure https://www.biopharmawatch.com/news/ACRV/acrivon-therapeutics-appoints-michaela-levin-cbo BiopharmaWatch en 2026-08-31T12:30:29.000Z Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer https://www.biopharmawatch.com/news/SUPN/chloe-kim-qelbree-adhd-awareness BiopharmaWatch en 2026-08-31T12:30:00.000Z Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-pf614-mpar-102-study-completion BiopharmaWatch en 2026-08-31T12:30:00.000Z Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-september-investor-conference BiopharmaWatch en 2026-08-31T12:30:00.000Z Allogene Therapeutics Announces Participation in September Investor Conference https://www.biopharmawatch.com/news/HYPR/hyperfine-lake-street-conference-participation BiopharmaWatch en 2026-08-31T12:15:00.000Z Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference https://www.biopharmawatch.com/news/AMRN/amarin-esc-congress-2026-findings BiopharmaWatch en 2026-08-31T12:15:00.000Z Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026 https://www.biopharmawatch.com/news/RNAZ/transcode-therapeutics-ttx-mc138-breast-cancer-study BiopharmaWatch en 2026-08-31T12:05:00.000Z TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis https://www.biopharmawatch.com/news/KLRS/kalaris-present-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-08-31T12:00:09.000Z Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/OKUR/onkure-therapeutics-morgan-stanley-conference BiopharmaWatch en 2026-08-31T12:00:07.000Z OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference https://www.biopharmawatch.com/news/GEHC/ge-healthcare-photonova-spectra-ce-mark BiopharmaWatch en 2026-08-31T12:00:00.000Z GE HealthCare’s Photonova™ Spectra gains CE Mark, expanding international access https://www.biopharmawatch.com/news/ABBV/abbvie-wells-fargo-healthcare-conference-2026 BiopharmaWatch en 2026-08-31T12:00:00.000Z AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/TDOC/teladoc-health-appoints-michael-grasher-cfo BiopharmaWatch en 2026-08-31T12:00:00.000Z Teladoc Health Appoints Michael Grasher as Chief Financial Officer https://www.biopharmawatch.com/news/AEON/aeon-biopharma-lake-street-capital-conference-2026 BiopharmaWatch en 2026-08-31T12:00:00.000Z AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference https://www.biopharmawatch.com/news/BIVI/biovie-address-lc-trial-bezisterim-long-covid BiopharmaWatch en 2026-08-31T12:00:00.000Z BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID https://www.biopharmawatch.com/news/XAIR/beyond-air-fda-breakthrough-lungfit-go-ntm-pd BiopharmaWatch en 2026-08-31T12:00:00.000Z Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-fda-type-d-meeting-cad-1005 BiopharmaWatch en 2026-08-31T12:00:00.000Z Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-08-31T12:00:00.000Z Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/PTGX/fda-approval-mimrylo-rusfertide-polycythemia-vera BiopharmaWatch en 2026-08-31T12:00:00.000Z US FDA Approval of MIMRYLO™(rusfertide) for Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV) https://www.biopharmawatch.com/news/CMMB/chemomab-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-08-31T12:00:00.000Z Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-narcan-nasal-spray-canada BiopharmaWatch en 2026-08-31T11:55:00.000Z Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-opioid-overdose-awareness BiopharmaWatch en 2026-08-31T11:54:00.000Z Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day https://www.biopharmawatch.com/news/AGEN/agenus-participate-september-investor-conferences BiopharmaWatch en 2026-08-31T11:30:00.000Z Agenus to Participate in Upcoming September Investor Conferences https://www.biopharmawatch.com/news/KPTI/karyopharm-submits-snda-fda-xpovio-ruxolitinib-myelofibrosis BiopharmaWatch en 2026-08-31T11:30:00.000Z Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-ndas-qtorin-rapamycin BiopharmaWatch en 2026-08-31T11:30:00.000Z Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-september-2026-investor-conferences BiopharmaWatch en 2026-08-31T11:00:07.000Z Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-conference-participation-2026 BiopharmaWatch en 2026-08-31T11:00:00.000Z Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/PLSM/pulsenmore-financial-results-h1-2026 BiopharmaWatch en 2026-08-31T11:00:00.000Z Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026 https://www.biopharmawatch.com/news/BLRX/biolinerx-reports-q2-2026-results-update BiopharmaWatch en 2026-08-31T11:00:00.000Z BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/LH/labcorp-global-trial-connect-enhancements BiopharmaWatch en 2026-08-31T11:00:00.000Z Labcorp Launches Next Generation of Labcorp Global Trial Connect™ to Help Sponsors and Investigator Sites Navigate Clinical Trial Complexity https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-summit-phase-3-trial-axs-05 BiopharmaWatch en 2026-08-31T11:00:00.000Z Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation https://www.biopharmawatch.com/news/ASND/ascendis-biomarin-global-settlement-yuviwel BiopharmaWatch en 2026-08-31T11:00:00.000Z Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide) https://www.biopharmawatch.com/news/TELA/tela-bio-coo-cfo-transition-cost-reduction BiopharmaWatch en 2026-08-31T11:00:00.000Z TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative https://www.biopharmawatch.com/news/HLF/herbalife-ceo-transition-stephan-gratziani BiopharmaWatch en 2026-08-31T10:50:00.000Z Herbalife Announces Planned CEO Transition https://www.biopharmawatch.com/news/ONC/beone-medicines-phase-3-ziihera-data-her2-cancer BiopharmaWatch en 2026-08-31T10:00:00.000Z BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-fda-type-c-meeting-ide849 BiopharmaWatch en 2026-08-31T10:00:00.000Z IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer https://www.biopharmawatch.com/news/NUTX/nutex-health-hospitals-community-honors-q2-2026 BiopharmaWatch en 2026-08-31T09:30:00.000Z Nutex Health Hospitals Earn Multiple Community Honors in Second Quarter 2026 https://www.biopharmawatch.com/news/ALVO/alvotech-fda-review-avt80-biosimilar BiopharmaWatch en 2026-08-31T08:30:00.000Z Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations https://www.biopharmawatch.com/news/AMGN/amgen-repatha-reduces-death-risk-heart-attack-stroke BiopharmaWatch en 2026-08-31T07:18:00.000Z AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-08-31 BiopharmaWatch en 2026-08-31T07:15:24.149Z Biotech Catalysts to Watch: Key Developments Ahead in Q4 2026 https://www.biopharmawatch.com/news/BMRN/biomarin-settlement-ascendis-yuviwel-royalties BiopharmaWatch en 2026-08-31T06:00:00.000Z BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea https://www.biopharmawatch.com/news/ALNY/alnylam-esc-congress-2026-data-rnai-therapy BiopharmaWatch en 2026-08-31T04:46:00.000Z Alnylam präsentiert auf dem ESC Congress 2026 neue Daten, die die Wirksamkeit des RNAi-basierten TTR-Silencing bei verschiedenen ATTR-CM-Patientengruppen und in verschiedenen Behandlungsumgebungen belegen https://www.biopharmawatch.com/news/ALNY/alnylam-esc-2026-rnai-therapy-data BiopharmaWatch en 2026-08-31T04:35:00.000Z Riassunto: Alnylam presenta nuovi dati al Congresso ESC 2026, rafforzando l'efficacia del silenziamento della transtiretina (TTR) basato sulla tecnologia RNAi nelle popolazioni di pazienti affetti da ATTR-CM e nei diversi contesti terapeutici https://www.biopharmawatch.com/news/ALNY/alnylam-esc-2026-transthyretin-silencing-data BiopharmaWatch en 2026-08-31T04:35:00.000Z Resumen: Alnylam presenta nuevos datos en el Congreso 2026 de la ESC que refuerzan la eficacia en el silenciamiento de la transtiretina mediante interferencia de ARN en poblaciones de pacientes y entornos de tratamiento de miocardiopatía amiloide por trans... https://www.biopharmawatch.com/news/ALNY/alnylam-esc-congress-2026-rnai-ttr-silencing BiopharmaWatch en 2026-08-31T04:35:00.000Z Samenvatting: Alnylam presenteert nieuwe gegevens op het ESC-congres 2026 en legt de nadruk op de effectiviteit van RNAi-gebaseerde TTR-silencing bij verschillende ATTR-CM-patiëntengroepen https://www.biopharmawatch.com/news/KZIA/kazia-therapeutics-oversubscribed-public-offering BiopharmaWatch en 2026-08-31T00:00:00.000Z Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively ... https://www.biopharmawatch.com/news/JAZZ/ziihera-chemotherapy-survival-benefit-her2-advanced-gea BiopharmaWatch en 2026-08-31T00:00:00.000Z Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced second interim top-line overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial... https://www.biopharmawatch.com/news/LLY/lilly-taltz-zepbound-phase-3b-results BiopharmaWatch en 2026-08-31T00:00:00.000Z New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity At Week 52, Taltz and Zepbound maintained or further improved psoriasis or psoriatic arthritis disease activity from Week 36, when statistically... https://www.biopharmawatch.com/news/BHC/bausch-health-launches-fraxel-ftx-australia BiopharmaWatch en 2026-08-31T00:00:00.000Z Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and its aesthetics business, Solta Medical, today... https://www.biopharmawatch.com/blog/biotech-stocks-hedge-funds-are-buying-q2-2026 BiopharmaWatch en 2026-08-30T22:41:03.361Z The 28 Biotech Stocks Hedge Funds Are Buying and Holding in 2026 (Q2 13F Special Report) https://www.biopharmawatch.com/news/ARWR/arrowhead-phase-3-shasta-3-4-plozasiran-results BiopharmaWatch en 2026-08-30T15:30:00.000Z Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia https://www.biopharmawatch.com/news/ALNY/alnylam-esc-congress-2026-data BiopharmaWatch en 2026-08-30T12:23:00.000Z Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings